Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A, Besley C, Chaganti S, Osborne W, Norman J, Gibb A, Sharplin K, Cuadrado M, Correia de Farias M, Cheok K, Neill L, Latif AL, González Arias C, Uttenthal B, Jones C, Johnson R, McMillan A, Sanderson R, Townsend W. Kuhnl A, et al. Br J Haematol. 2023 Jul;202(1):65-73. doi: 10.1111/bjh.18810. Epub 2023 Apr 20. Br J Haematol. 2023. PMID: 37082780
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Kühnl A, et al. Ann Oncol. 2017 Jul 1;28(7):1540-1546. doi: 10.1093/annonc/mdx128. Ann Oncol. 2017. PMID: 28398499 Free PMC article. Clinical Trial.
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Kühnl A, Peckitt C, Patel B, Ardeshna KM, Macheta MP, Radford J, Johnson R, Paneesha S, Barton S, Chau I, Begum R, Valeri N, Wotherspoon A, Du Y, Zerizer I, Cunningham D. Kühnl A, et al. Ann Hematol. 2020 Jan;99(1):105-112. doi: 10.1007/s00277-019-03842-4. Epub 2019 Nov 27. Ann Hematol. 2020. PMID: 31776726 Clinical Trial.
Correction to: ICU-outcomes in CAR-T patients-A single centre experience.
Materski T, John M, Pirani T, Benjamin R, Kuhnl A, Potter V, Sanderson R, Metaxa V. Materski T, et al. Among authors: kuhnl a. Intensive Care Med Exp. 2021 Feb 18;9(1):9. doi: 10.1186/s40635-021-00370-2. Intensive Care Med Exp. 2021. PMID: 33599849 Free PMC article. No abstract available.
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.
Kuhnl A, Roddie C, Kirkwood AA, Menne T, Cuadrado M, Marzolini MAV, Osborne W, Sanderson R, O'Reilly M, Townsend W, Benjamin R, Potter V, Patten PEM, Yallop D, Voo S, Petrides GS, Mulholland N, Kayani I. Kuhnl A, et al. Blood Adv. 2022 Jan 11;6(1):321-326. doi: 10.1182/bloodadvances.2021005807. Blood Adv. 2022. PMID: 34700342 Free PMC article. No abstract available.
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Northend M, et al. Among authors: kuhnl a. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. Blood Adv. 2022. PMID: 35020818 Free PMC article. No abstract available.
73 results